Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis
- First Online:
- Cite this article as:
- He, Y., Mou, Z., Li, W. et al. Int J Colorectal Dis (2009) 24: 1271. doi:10.1007/s00384-009-0759-2
- 272 Downloads
Background and aims
Sera from cancer patients contain tumor-specific autoantibodies directly against antigenic proteins. The identification of tumor autoantigens may have utility in cancer diagnosis, prognosis, and therapy. In this study, we used immunoproteomics analysis to identify tumor proteins that elicit humoral response in colorectal cancer (CRC).
Materials and methods
The CRC cell line HCT116 was used as a source of proteins for two-dimensional polyacrylamide gel electrophoresis and subsequent Western blot analysis in which individual serum from patients with CRC was analyzed for autoantibodies. Proteins that specifically react with sera from cancer patients were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometric analysis. In addition, the selected protein expression in tumor tissues collected from 40 patients with CRC were assessed by immunohistochemistry.
An autoantibody against inosine monophosphate dehydrogenase II (IMPDH2) identified by mass spectrometry was detected in eight out of 25 patients with CRC. However, none of the 15 healthy controls demonstrated autoantibody to IMPDH2.The expression of IMPDH2 in tumor tissue was significantly higher in patients with CRC than that in healthy subjects.
The result confirmed that the immunoproteomics analysis holds considerable promise for the discovery of tumor-associated antigens. IMPDH2 may be a protein biomarker and novel therapeutic target in CRC.
KeywordsColorectal cancer Immunoproteomics analysis Tumor-associated antigens Inosine monophosphate dehydrogenase II (IMPDH2)
- 2-D PAGE
two-dimensional polyacrylamide gel electrophoresis
matrix-assisted laser desorption ionization time-of-flight
inosine monophosphate dehydrogenase II